α4β7 Integrin Blockade for GI Toxicity in Immune Oncology

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Immune oncology treatments, such as those using anti-CTLA4 and anti-PD-1 antibodies, often result in significant gastrointestinal immune-related adverse events (gi-irAEs) like colitis and diarrhea, leading to treatment interruptions and discontinuations in up to 40% of subjects, necessitating a need for effective methods to reduce these adverse effects without compromising treatment efficacy.

Innovation Solution

Administering a polypeptide that inhibits MAdCAM-α4β7 integrin binding, such as anti-α4β7 integrin antibodies, to subjects undergoing immune oncology treatments, which reduces gi-irAEs without affecting the efficacy of the immune therapy and with a better safety profile compared to systemic treatments like corticosteroids or anti-TNF agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If immune oncology treatments (anti-CTLA4 and anti-PD-1 antibodies) are administered to treat cancer, then treatment efficacy against cancer is improved, but gastrointestinal immune-related adverse events (colitis and diarrhea) increase significantly

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidgastrointestinal immune-related adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the immune system response by selectively targeting gut-homing lymphocytes through MAdCAM-1 inhibition, rather than broadly suppressing the entire immune system. This allows cancer-fighting immunity to remain active while specifically blocking the pathway that leads to gastrointestinal inflammation and adverse events.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention introduces MAdCAM-1 inhibitors as an intermediary agent that mediates between the immune oncology treatment and the gastrointestinal tract. These inhibitors block the interaction between MAdCAM-1 on gut endothelial cells and its ligands on lymphocytes, preventing harmful immune cell infiltration into the gut while allowing the immune therapy to continue systemically.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If systemic treatments (corticosteroids or anti-TNF agents) are used to reduce gastrointestinal adverse events, then gi-irAEs are ameliorated, but treatment efficacy of immune therapy is significantly reduced

Engineering Contradiction:

Improvegastrointestinal immune-related adverse eventsVSAvoidimmune therapy efficacy

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention applies local quality by specifically targeting the gastrointestinal tract's lymphocyte recruitment pathway through MAdCAM-1 inhibition, rather than applying systemic immunosuppression. This localized approach reduces gi-irAEs in the gut while preserving the systemic immune response needed for cancer treatment efficacy.

Inventive Principle:

Principle #3Local quality

3Reliability

If immune oncology treatment is continued without intervention, then cancer treatment efficacy is maintained, but treatment interruptions and discontinuations increase due to severe gi-irAEs

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidtreatment continuity

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention applies preliminary action by administering MAdCAM-1 inhibitors either before or at the onset of gi-irAEs to prevent severe gastrointestinal adverse events before they occur. This proactive approach allows immune oncology treatment to continue without interruption by preemptively blocking the pathological immune response in the gut.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of polypeptides that inhibit MAdCAM-α4β7 integrin binding significantly reduces gi-irAEs, enhancing treatment compliance, maintaining efficacy, and minimizing the need for additional medications, with potential reductions in hospitalizations and endoscopy procedures.

Implementation Method 1

a polypeptide that inhibits MAdCAM-α4β7 integrin binding, such as an anti-α4β7 integrin antibody

Methodology Applied

Scientific EffectMAdCAM-α4β7 integrin binding inhibition:

Data Source

PatentUS12590157B2Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments

Publication Date: 2026.03.31 TAKEDA PHARMA CO LTD

AI summary

The invention provides, inter alia, methods of reducing gastrointestinal immune-related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods encompass administering a therapeutically effective amount of a polypeptide that inhibits MAdCAM-integrin binding, such as an anti-α4β7 integrin antibody, such vedolizumab or a related antibody.